key: cord-0944918-sxbwizpa
authors: Lippi, Giuseppe; Mattiuzzi, Camilla; Henry, Brandon M.
title: Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant
date: 2022-01-12
journal: J Med Virol
DOI: 10.1002/jmv.27575
sha: 0be83a140c4ce7c86bce18b5353dd1b8ccbfb4b8
doc_id: 944918
cord_uid: sxbwizpa

The recent emergence of a new variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called Omicron (B.1.1.529) has raised paramount concerns in scientific and medical communities due to the presence of several mutations in the spike protein, many of which are located within the receptor binding domain (RBD).1 Some of these mutations were found to have a substantial influence on host cells receptor and anti-SARS-CoV-2 antibodies binding,2 which may then impact infectivity and neutralizing antibodies escape, thus potentially magnifying the risk of COVID-19 (coronavirus disease 2019) vaccine breakthrough. We have hence carried out a scientific literature search, aimed at summarizing the currently published evidence on Omicron variant neutralizing properties of serum or plasma collected from recipients of COVID-19 vaccines.

We carried out an electronic search in Medline and Scopus, using the keywords "vaccine" AND "Omicron" OR "B.1.1.529" AND "SARS-CoV-2" AND "neutralization" OR "antibodies," with no language or date limits (i.e., up to January 2, 2022). Title, summary, and (even- Overall, 52 items could be originally detected based on our search criteria, and seven more could be identified from the reference lists, thus leading to 59 potentially eligible studies. Nonetheless, 45 of such documents ought to be omitted since they did not fulfill our aforementioned search criteria. Our final analysis could thus only include 14 published studies (Table 1) 

Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa

Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective

Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Booster of mRNA-1273 vaccine reduces SARS-CoV-2 Omicron escape from neutralizing antibodies. medRxiv

Plasma neutralization properties of the SARS-CoV-2 Omicron variant

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or coronavac vaccine recipients

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv

Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera. medRxiv

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. medRxiv

Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv

Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Res Sq

Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection